Following yesterday’s closing bell, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced positive Phase 3 results from two highly anticipated studies evaluating the tezacaftor and ivacaftor (Kalydeco) …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are up nearly 6% in pre-market trading Wednesday, after the drug maker laid out a development plan for …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported consolidated financial results for the quarter ended June 30, 2016 and reviewed recent progress with its approved and investigational …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that the U.S.
AEterna Zentaris Inc. (USA) In a research issued yesterday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of AEterna Zentaris Inc.
Analysts have mixed sentiments on MannKind Corporation (NASDAQ:MNKD) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). It’s a long fall from the top as MannKind investors …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that it received a Complete Response Letter from theU.S.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported consolidated financial results for the quarter endedDecember 31, 2015. Vertex also reiterated its financial guidance for total 2016 KALYDECO® (ivacaftor) …
J.P.
